Dr Daren Austin

Honorary Resea rch Fellow & Clinical Pharmacologist at GlaxoSmithKline

Dr Austin’s research interests focus on the use of mathematical models to predict the outcome for outbreaks in small settings. He is particularly interested in the dynamics of hospital outbreaks of resistant organisms, which are highly transmissible and often difficult to control. These “nosocomial” or hospital-acquired infections have received considerable attention in the media. As a Clinical Pharmacologist he works on the development of therapeutic monoclonal antibodies, where he heads a group responsible for clinical trial design and prediction of therapeutic regimens primarily in the treatment of inflammatory disease.